Want to see FR:ALIMP full AI Analyst Report?
Implanet SA (ALIMP) Stock Price & Analysis
ALIMP Stock Chart & Stats
- Day’s Range
- EUR 0.13 - EUR 0.14
- 52-Week Range
- EUR 0.13 - EUR 0.29
- Previous Close
- EUR 0.15
- Volume
- N/A
- Average Volume (3M)
- 68.50K
- Market Cap
- EUR 21.29M
- Enterprise Value
- EUR 28.61M
- Total Cash (Recent Filing)
- EUR 1.01M
- Total Debt (Recent Filing)
- EUR 5.46M
- Price to Earnings (P/E)
- ―
- Beta
- 0.01
- Next Earnings
- Mar 09, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound
The strong multi-year revenue rebound indicates improving commercial traction for Implanet’s orthopedic and spine products. Continued top-line expansion can support greater operating scale, broader surgeon and hospital adoption, and a stronger foundation for eventual profitability.
Gross Margin Expansion
Meaningful gross-margin expansion improves the economic contribution of each product sale and creates more room to cover operating expenses. If maintained alongside revenue growth, this improvement could strengthen the company’s path toward reducing losses and funding future development.
Improving Operating Cash Flow
Although operating cash flow remains negative, the substantial year-over-year improvement suggests that cash absorption is moderating as the business expands. Sustaining this direction would reduce reliance on external funding and improve financial flexibility over the next several quarters.
Bears Say
Persistent Net Losses
Persistent operating and net losses show that revenue growth and higher gross margins have not yet translated into a sustainable earnings model. Continued losses can consume capital, restrict investment capacity, and delay the point at which growth becomes self-financing.
Negative Free Cash Flow
Ongoing negative free cash flow means Implanet is not yet generating enough cash internally to support its operations and investment needs. Until free cash flow turns sustainably positive, the company may remain dependent on financing and face less flexibility during periods of weaker performance.
High Leverage And Thin Equity
The very high debt load relative to a minimal equity base leaves limited protection against continued losses and weakens balance-sheet resilience. Prior negative equity also highlights material financial stress, while leverage can constrain capital allocation and increase dependence on funding support.
Implanet SA News
ALIMP FAQ
What was Implanet SA’s price range in the past 12 months?
What is Implanet SA’s market cap?
When is Implanet SA’s upcoming earnings report date?
How were Implanet SA’s earnings last quarter?
Is Implanet SA overvalued?
Does Implanet SA pay dividends?
What is Implanet SA’s EPS estimate?
How many shares outstanding does Implanet SA have?
What happened to Implanet SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Implanet SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Implanet SA
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ludovic Lastennet
- Employees
- 49
- Website
- www.implanet.com
- Address
- Technopole Bordeaux Montesquieu, Martillac, NA, 33650, FR
Implanet SA (ALIMP) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |


